Insomnia News and Research

Latest Insomnia News and Research

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

16 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Transcept Pharmaceuticals reports financial results for the third quarter of 2009

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience, today announced financial results for the three and nine months ended September 30, 2009.

13 Nov 2009

Mental Health America and Prescription Audio team up to provide free sound therapy

Mental Health America today announced it is partnering with Prescription Audio, a Philadelphia-area based firm (Voorhees, N.J.), to make the company's scientifically based sound therapy available without charge as a download to veterans, active duty servicemen and women, their family members and health care providers.

12 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

Computerized alerts induce clinicians to prescribe comparable generic equivalents

Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs. A study in the August issue of Journal of General Internal Medicine found that when clinicians received computerized alerts, which compared medication brands, they changed 23.3 percent of prescriptions for four heavily marketed sleep medications to comparable generic equivalents.

10 Nov 2009

USPTO issues Notice of Allowance to NovaDel Pharma

NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

6 Nov 2009

CHANTIX/CHAMPIX raises hope for quitting smoking

New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP).

5 Nov 2009

Green tea holds hope for prevention of oral cancer

Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Nov 2009

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

5 Nov 2009

Takeda Pharmaceuticals strengthens its North American market

Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the company's North American presence, bolstering existing operations in the United States and Canada. Takeda Pharmaceuticals Mexico will be headquartered in Mexico City.

4 Nov 2009

ASTI's 'Tell-a-Friend program' for solving sleep-related problems

Adaptive Sound Technologies, Inc. (ASTI) announced today that it will pay cash rewards to ASTI customers who refer friends that in turn buy an Ecotones or Ecotones Duet directly from ASTI. The new "Tell-a-Friend" program rewards customers for doing what they have been doing since the first Ecotones was introduced late last year: letting friends in on the secret to better sleep.

4 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

NUVIGIL improves wakefulness in patients with excessive sleepiness associated with shift work disorder

Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).

3 Nov 2009

Vanda Pharmaceuticals announces financial results for the third quarter of 2009

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2009.

2 Nov 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Insomnia News and Research

Latest Insomnia News and Research

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire announces findings from Phase 3 study data with Vyvanse

Transcept Pharmaceuticals reports financial results for the third quarter of 2009

Mental Health America and Prescription Audio team up to provide free sound therapy

Potential benefits of Labopharm's novel trazodone formulation published

Computerized alerts induce clinicians to prescribe comparable generic equivalents

USPTO issues Notice of Allowance to NovaDel Pharma

CHANTIX/CHAMPIX raises hope for quitting smoking

Green tea holds hope for prevention of oral cancer

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

Takeda Pharmaceuticals strengthens its North American market

ASTI's 'Tell-a-Friend program' for solving sleep-related problems

Interim data from Schering-Plough's narlaprevir Phase IIa study

NUVIGIL improves wakefulness in patients with excessive sleepiness associated with shift work disorder

Vanda Pharmaceuticals announces financial results for the third quarter of 2009

Shire announces Phase IIIb study results of Daytrana

Schering-Plough receives FDA complete response letter regarding PEGINTRON

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Insomnia News and Research

Latest Insomnia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in